In a stunner, Merck leaps ahead of rivals with combo Keytruda/chemo attack on lung cancer
Merck’s immuno-oncology team has become expert at pressing an early advantage.
The Keytruda company, which recently trounced Bristol-Myers in their rivalry on lung cancer, has now filed an early and stunning application to market a combination of Keytruda and chemo for first-line lung cancer. And the move has the potential to carve out a shortcut that will allow them to cut ahead of a struggling AstraZeneca and a potent Roche.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.